Fosinopril Sodium

Dual blockade of RAS is associated with increased risks of hypotension, hyperkalemia, and changes in renal function.

Dual blockade of RAS is associated with increased risks of hypotension, hyperkalemia, and changes in renal function.

Increased serum lithium levels and symptoms of lithium toxicity have been reported. Frequent monitoring of serum lithium levels is recommended.

Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.

In elderly, volume-depleted, or renal-impaired patients, may result in deterioration of renal function including acute renal failure. May attenuate antihypertensive effect.

Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.

Nitritoid reactions (facial flushing, nausea, vomiting, hypotension) have been reported rarely with concomitant ACE inhibitor therapy.

Patients taking concomitant mTOR inhibitor therapy may be at increased risk for angioedema.

Reduces serum levels and urinary excretion of fosinoprilat. Dosing should be separated by 2 hours.

Potassium-sparing diuretic that can increase risk of hyperkalemia when combined with fosinopril. Serum potassium should be monitored frequently.

Diuretics, especially those causing intravascular volume depletion, may cause excessive reduction of blood pressure after initiation of fosinopril therapy. Patient should be observed closely and starting dose may need reduction.

NSAIDs may deteriorate renal function in elderly, volume-depleted, or renally compromised patients, and may attenuate antihypertensive effect of fosinopril. Periodic renal function monitoring recommended.

Reduces serum levels and urinary excretion of fosinoprilat. Dosing should be separated by 2 hours.

Monitor renal function periodically in patients receiving quinapril and NSAID therapy.

Reduces serum levels and urinary excretion of fosinoprilat. Dosing should be separated by 2 hours.

Potassium-sparing diuretic that can increase risk of hyperkalemia when combined with fosinopril. Serum potassium should be monitored frequently.

Potassium-sparing diuretic that can increase risk of hyperkalemia when combined with fosinopril. Serum potassium should be monitored frequently.

Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia.

In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propranolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.

In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propranolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.

In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propranolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.

In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propranolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.